



For Immediate Release: Tuesday, May 5, 2009

## **NEWS RELEASE**

Contact: Howard Root, CEO  
James Hennen, CFO  
Vascular Solutions, Inc.  
(763) 656-4300

### **VASCULAR SOLUTIONS TO PARTICIPATE IN BANK OF AMERICA SECURITIES 2009 HEALTH CARE CONFERENCE**

MINNEAPOLIS, Minnesota -- Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to participate in the Bank of America Securities Health Care Conference being held next week at The Palace Hotel in New York City.

James Hennen, Chief Financial Officer of Vascular Solutions, will present on Tuesday, May 12<sup>th</sup> at 2:40pm (EST). To hear the live audio webcast of the panel discussion, go to the investor relations page of the Company's web site <http://www.vascularsolutions.com> and click on the "IR Conferences" icon a few minutes prior to start time to download any necessary software.

#### **About Vascular Solutions**

Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company's product line consists of five major categories: hemostat (blood clotting) products, extraction (clot removal) catheters, vein products, specialty catheters and access products. Vascular Solutions delivers its proprietary and distributed products to interventional cardiologists, interventional radiologists and vascular surgeons through its direct U.S. sales force and international distributor network.

The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2008 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, limited working capital, lack of sustained profitability, exposure to intellectual property claims, exposure to possible product liability claims, the development of new products by others, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, and actions by the FDA.

For further information, connect to [www.vascularsolutions.com](http://www.vascularsolutions.com).